Syndex Bio

Founded in 2022 and headquartered in Cambridge, UK, Syndex Bio Limited specializes in genomic technologies, particularly through its innovative mcPCR platform.Syndex Bio specializes in the development of its proprietary mcPCR™ technology, which stands for methyl copying PCR. This innovative platform enables the amplification of DNA methylation alongside traditional DNA sequences, addressing a critical limitation of conventional PCR methods that cannot replicate the 5mC signal. By preserving DNA methylation patterns during amplification, mcPCR facilitates enhanced analysis of methylated DNA, which is particularly valuable in clinical settings where sample sizes may be limited. The technology is tailored for applications in oncology testing, early cancer detection, residual disease monitoring, and chronic disease tracking, making it essential for researchers and clinicians focused on disease diagnostics and treatment strategies.Syndex Bio's revenue model is primarily driven by partnerships and collaborations with research institutions and clinical laboratories that require advanced genomic analysis tools. The company offers its mcPCR technology through direct sales and potentially subscription-based agreements, where clients gain access to the technology for ongoing research projects or clinical applications. These transactions are structured around multi-omic analyses, allowing clients to integrate mcPCR seamlessly into existing workflows. Syndex Bio's flagship product, mcPCR, is positioned as a crucial tool in the molecular biology landscape, supporting high-throughput processing for various clinical applications.5 mn, Syndex Bio Limited aims to enhance its mcPCR platform and develop new clinical workflows and applications. The company plans to expand into North America, Europe, and select regions in Asia by the end of 2027, focusing on markets with a growing need for genomic analysis technologies.

1. Seed

   Feb 23, 2026

   Amount

   $16M

   Investors

   Locked